Martin A. Bruno

Martin A. Bruno

Auto-generated profile, based on publicly available information

Martin A. Bruno

Instituto de Ciencias Biomédicas (ICBM), Facultad de Ciencias Médicas, Universidad Católica de Cuyo, San Juan, Argentina

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 March 2021 in ACS Nano
Verified
Journal Article
Open access
MGMaría Eugenia Navas Guimaraes
María Eugenia Navas Guimaraes
RLRoi Lopez-Blanco
Roi Lopez-Blanco
JCJuan Correa
Juan Correa
MFMarcos Fernandez-Villamarin
Marcos Fernandez-Villamarin
MBMaría Beatriz Bistué
María Beatriz Bistué
MBMartin A. Bruno
Martin A. Bruno
The progressive accumulation of amyloid-beta (Aβ) in specific areas of the brain is a common prelude to late-onset of Alzheimer’s disease (AD). Although activation of liver X receptors (LXR) with agonists decreases Aβ levels and ameliorates contextual memory deficit, concomitant hypercholesterolemia/hypertriglyceridemia limits their clinical application. DMHCA (N,N-dimethyl-3β-hydroxycholenamide) is an LXR partial agonist that, despite inducing the expression of apolipoprotein E (main responsible of Aβ drainage from the brain) without increasing cholesterol/triglyceride levels, shows nil activity in vivo because of a low solubility and inability to cross the blood brain barrier. Herein, we describe a polymer therapeutic for the delivery of DMHCA. The covalent incorporation of DMHCA into a PEG-dendritic scaffold via carboxylate esters produces an amphiphilic copolymer that efficiently self-assembles into nanometric micelles that exert a biological effect in primary cultures of the central nervous system (CNS) and experimental animals using the intranasal route. After CNS biodistribution and effective doses of DMHCA micelles were determined in nontransgenic mice, a transgenic AD-like mouse model of cerebral amyloidosis was treated with the micelles for 21 days. The benefits of the treatment included prevention of memory deterioration and a significant reduction of hippocampal Aβ oligomers without affecting plasma lipid levels. These results represent a proof of principle for further clinical developments of DMHCA delivery systems.

15 July 2025 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
MMMaria Beatriz Bistue Millón
Maria Beatriz Bistue Millón
LNLaura Noguera
Laura Noguera
DBDiana Bruno
Diana Bruno
LVLuciana Vita
Luciana Vita
MZMariana Zanino
Mariana Zanino
MBMartin A. Bruno
Martin A. Bruno

1 December 2017 in Revista Argentina de Anestesiología
Verified
Journal Article
Closed access
LSL.A. Neculpán Segura
L.A. Neculpán Segura
MBM.A. Bruno
M.A. Bruno